New Publication from Vizeacoumar and Freywald Labs in Oncotarget

"Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment"

Authors: Paul JM, Toosi B, Vizeacoumar FS, Bhanumathy KK, Li Y, Gerger C, El Zawily A, Freywald T, Anderson DH, Mousseau D, Kanthan R, Zhang Z, Vizeacoumar FJ, Freywald A.

Oncotarget. 2016 Jul 13. doi: 10.18632/oncotarget.10569. [Epub ahead of print]  PMID: 27418135

 The paper can be accessed here: http://www.ncbi.nlm.nih.gov/pubmed/27418135